This review will discuss the therapies (apart from bone marrow transplant) currently used to treat splenomegaly and splenomegaly-related symptoms in patients with MF and the potential role of the JAK2 (as well as JAK1/JAK2) inhibitors. This evidence concerns the gene JAK1 and Splenomegaly.